Key result
Ginsenoside Rg3 plus cyclophosphamide extends survival ~98% versus control in a lung cancer mouse model.
Why the study?
The effectiveness of ginsenoside Rg3 alone or combined with cyclophosphamide on tumor growth and angiogenesis in human lung cancer was evaluated.
Does ginsenoside Rg3 alone or in combination with cyclophosphamide reduce tumor growth and angiogenesis in a mouse model of human lung cancer?
Does ginsenoside Rg3 alone or in combination with cyclophosphamide reduce tumor growth and angiogenesis in a mouse model of human lung cancer?
Ginsenoside Rg3, alone or combined with cyclophosphamide, inhibits tumor growth and angiogenesis and improves survival in a mouse model of lung cancer.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in lung cancer models; human trials needed before any clinical consideration.
To evaluate the effectiveness of ginsenoside Rg3 alone or in combination with cyclophosphamide (CPA) on tumor growth and angiogenesis in human lung cancer, 54 female athymic mice were transplanted with lung cancer cells (A549) which then were randomly divided into 4 groups: Ginsenoside Rg3 group, CPA group, ginsenoside Rg3 plus CPA group and control group. Ginsenoside Rg3 of 3.0 mg/kg (once/day for 10 days) and CPA of 20.0 mg/kg (once/day for 10 days) were intraperitoneally given to mice for consecutive 10 days. Seven mice selected from each group were sacrificed 18 days later. The survival time of the remaining 7 mice in each group was recorded. The life elongation rate, proliferating cell nuclear antigen labeling index (PCNALI), expression of vascular endothelial cell growth factor (VEGF) and microvessel density (MVD) in the tumor tissues were evaluated. The quality of life of mice with administration of ginsenoside Rg3 alone or ginsenoside Rg3 plus CPA were better with longer survival time, when compared with other groups. The PCNALI, MVD and VEGF expression in mice of the treated groups were significantly lowered when compared with that of the control group. Additionally, the MVD of mice in groups with treatment of ginsenoside Rg3 alone or ginsenoside Rg3 plus CPA were lower than that in the CPA group. Tumor growth and angiogenesis in lung cancer were profoundly inhibited by ginsenoside Rg3 alone or in combination with CPA. The synergistic anticancer effects of ginsenoside Rg3 and CPA improved the survival time in lung cancer.
No takes yet. Share an insight, caveat, or question.
Li et al. (2011) studied Lung cancer (n=54). Ginsenoside Rg3 and cyclophosphamide vs. Saline (control) was evaluated on Survival time (days) (Life elongation rate 98.2%, p=<0.01). Ginsenoside Rg3 combined with cyclophosphamide prolonged survival time in a mouse model of lung cancer compared to control.
Synapse has enriched 10 related papers. Consider them for comparative context: